Genomic DNA from reported samples underwent whole-exome sequencing (WES) as described previously and below11 (link),14 (link). The SeqCap EZ Exome v2.0 (Roche Life Science), xGen Exome Research Panel (Integrated DNA Technologies), or SeqCap EZ MedExome (Roche Life Science) kit was used for capture. After library preparation, sequencing was performed on the Illumina HiSeq platform (RRIDs: SCR_016386, SCR_016383, SCR_016387) with paired-end 74 or 100 base pair reads. The tumor and blood samples were sequenced to a target depth of 185 and 85 reads, respectively. Sequenced reads were aligned to the human reference genome (GRCh37) using BWA-mem (version 0.7.15)58 . PCR duplicates were marked with Picard (version 2.17.11, RRID:SCR_006525)59 , followed by local realignment and base quality recalibration using Genome Analysis Toolkit (GATK, version 3.4, RRID:SCR_001876)60 (link).
Free full text: Click here